Home > Cardiology > FDA approves Eli Lilly drug to cut death, hospitalization risk in all heart failure patients

FDA approves Eli Lilly drug to cut death, hospitalization risk in all heart failure patients


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Reuters - 24/02/2022 - The U.S. health regulator said on Thursday it had approved Eli Lilly and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure. Originally approved by the Food and Drug Administration in 2014 for type 2 diabetes patients, the drug's use was expanded last year in some adults living with heart failure with reduced ejection fraction. "While Jardiance may not be effective in all patients with heart failure, this approval is a significant step forward for patients and our understanding of heart failure," said Norman Stockbridge, director of the FDA's Division of Cardiology and Nephrology. The expansion on Thursday now increases its market size to cover a very large patient population of about 6.2 million people, as per Centers for Disease Control and Prevention data. Jardiance also faces competition from AstraZeneca Plc's drug Farxiga, whi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on